Table 1.
Overview of the included articles (n=7)
| Studies on follow-up | n | Scanner AJCC Stage Examination | Inclusions criteria | Prospective/retrospective | Interpretation | Reference standard |
|---|---|---|---|---|---|---|
| 2012 | 97 | FDG-PET/CT | Patients undergoing ILI and who had a pre-PET/CT done before ILI and post-PET/CT done 3-monthly following surgery. | Prospective | Visual qualitative | Fine needle aspiration, CT guided biopsy and subsequent surgical resection when feasible. |
| Beasley [17] | Stage IIIB (n=61), IIIC (n=29) and IV (n=3) | 2004-2010 | ||||
| Therapy resp. | Database | |||||
| Follow-up | ||||||
| 2011 | 188 | FDG-PET/CT | Symptomatic patients undergoing ILI and/or HILP. PET/CT done pre and post-treatment (3-monthly for a year and then every 6 months thereafter). | Prospective | NA | Pathological and clinical response to ILI/HILP at 3 months. |
| Raymond [18] | Advanced extremity melanoma | 1995-2010. | ||||
| Stage IIIB, IIIC and IV. | Database | |||||
| Therapy resp. | ||||||
| Follow-up | ||||||
| 2011 | 20 | FDG-PET/CT | First annual surveillance PET/CT performed 12-23 months following diagnosis or development of stage III disease on an asymptomatic adult patient. Annual surveillance PET/CT. | Retrospective | Visual qualitative | NA |
| Abbott [19] | Micro. stage III | May 2008 | ||||
| Follow-up | Database | |||||
| 14 | FDG-PET/CT | |||||
| Macro. stage III | ||||||
| Follow-up | ||||||
| 2011 | 115 | FDG-PET/CT | Symptomatic (n=82) and asymptomatic (n=33) patients with and without increased levels of protein S-100B. | Prospective | Visual evaluation and semiquantitative analysis by measuring SUV max | Fine-needle aspiration cytology, CT, MRI, US, radiological findings, histology report |
| Peric [20] | Stage I (18%), II (41%), III (35%) and IV (4%). | Sept. 2007-feb. 2010 | ||||
| Follow-up | Database | |||||
| 2007 | 30 | FDG-PET | Asymptomatic patients | Prospective | Visual qualitative | Histology, CT and follow-up |
| Koskivuo [15] | Stage IIB-IIIC | March 2004-nov. 2005 | ||||
| Follow-up | Database | |||||
| 2006 | 250 | FDG-PET/CT | Patients referred for: | Retrospective | Visual qualitative | PET, CT and standard references – histological and clinical follow-up (bone scan, MRI and biopsy). |
| Reinhardt [21] | A comparison of PET, CT and PET/CT | Staging n=75, | Nov. 2002-June 2004 | |||
| Therapy resp. | Therapy response n=42 | Database | ||||
| Follow-up | Recurrence staging n=65 | |||||
| Follow-up n=68 | ||||||
| 1999 | 45 | FDG-PET | Patients with high risk of recurrence, clinical suspicion of recurrent disease, or recurrent melanoma. | Retrospective | Visual evaluation and semi quantitative analysis by measuring SUV max | Biopsy or other imaging modality within 6 weeks, or clinical follow-up within 6 months. |
| Nguyen [16] | High risk/recurrent melanoma | 1996-1998 | ||||
| Follow-up | Database |
AJCC, American Joint Committee on Cancer; CMM, Cutaneous malignant melanoma; CT, Computed tomography; FDG, Fluorine-18 labelled 2-deoxy-2-fluoro-D-glucose; US, Ultrasound; HILP, Hyperthermic isolated limb perfusion; ILI, Isolated limb infusion; MRI, Magnetic resonance imaging; NA, not available; PET, Positron Emission Tomography; SUV, Standardized uptake value.